Cargando…
A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab
Secukinumab is an IgG monoclonal antibody widely used for treatment of ankylosing spondylitis, psoriasis, and psoriatic arthritis. Recently, there has been increasing controversy regarding potential adverse effects of the drug especially in those with underlying inflammatory bowel disease. We presen...
Autores principales: | Achufusi, Ted George, Harnee, Prateek S., Rawlins, Sekou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701396/ https://www.ncbi.nlm.nih.gov/pubmed/31467555 http://dx.doi.org/10.1155/2019/2975631 |
Ejemplares similares
-
Corrigendum to “A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab”
por: Achufusi, Ted George, et al.
Publicado: (2019) -
A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
por: Ehrlich, Dean, et al.
Publicado: (2018) -
Abdominal Cerebrospinal Fluid Pseudocyst as a Complication of Ventriculoperitoneal Shunt Placement
por: Achufusi, Ted George O, et al.
Publicado: (2020) -
Secukinumab-Induced Lymphocytic Colitis
por: Gandu, Siva Santosh Kumar, et al.
Publicado: (2022) -
New onset severe ulcerative colitis following Ixekizumab therapy
por: Morosanu, Alina Mihaela, et al.
Publicado: (2022)